Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT00002324
Ignite Creation Date: 2024-05-05 @ 11:07 AM
Last Modification Date: 2024-10-26 @ 9:02 AM
Study NCT ID: NCT00002324
Protocol Section: NCT00002324
Start Identification Module Data
Expand Identification Module Data
Brief Title: The Safety and Effectiveness of Nevirapine and Zidovudine Given Separately and Together in HIV-1 Infected Patients Who Have No Symptoms of the Disease
Official Title: A Multi-Center Placebo-Controlled Double-Blind Randomized Trial Comparing the Activity Safety and Tolerance of 1 400 Mg Nevirapine in Combination With 500-600 Mg Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 3-24 Months of Prior Zidovudine Therapy and 200-500 CD4 Cellsmm3 and 2 400 Mg Nevirapine Versus Nevirapine Placebo in Asymptomatic HIV-1 Nucleoside Naive Patients With 200-500 CD4 Cellsmm3
Acronym: None
Organization: NIH AIDS Clinical Trials Information Service
Organization Class: INDUSTRY
Organization Study ID: 200C
Secondary IDs
Secondary ID Type Domain Link
1038 None None None
Start Status Module Data
Status Verified Date: 2002-08
Overall Status: COMPLETED
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Boehringer Ingelheim
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Boehringer Ingelheim
Start Oversight Module Data No Oversight Module Defined
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload